Recent Investment Analysts’ Ratings Updates for Abbott Laboratories (ABT)

Abbott Laboratories (NYSE: ABT) recently received a number of ratings updates from brokerages and research firms:

• 7/1/2026 – Abbott Laboratories is now covered by Robert W. Baird. They set an “outperform” rating and a $121.00 price target on the stock.
• 6/30/2026 – Abbott Laboratories was upgraded by Robert W. Baird to “strong-buy”.
• 6/22/2026 – Abbott Laboratories had its “overweight” rating reaffirmed by Piper Sandler. They now have a $115.00 price target on the stock.
• 6/16/2026 – Abbott Laboratories was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 6/12/2026 – Abbott Laboratories had its price target lowered by Bank of America Corporation from $120.00 to $102.00.
• 5/27/2026 – Abbott Laboratories had its price target lowered by The Goldman Sachs Group, Inc. from $121.00 to $113.00. They now have a “buy” rating on the stock.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.6%. Abbott Laboratories’s dividend payout ratio is 70.59%.

Insiders Place Their Bets

In related news, CFO Philip P. Boudreau purchased 2,200 shares of the firm’s stock in a transaction on Thursday, April 23rd. The stock was acquired at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the acquisition, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. This represents a ? increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction on Monday, April 27th. The shares were bought at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is owned by insiders.

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.